Altria
NYSE: MO
$72.73 ▲ +1.19  (+1.66%)
At close: Jul 2, 2026 · 3:59 PM UTC
Financial Ratios
Market Cap66.91 Bn
P/E8.31
P/S2.85
Div. Yield0.10
ROIC (Qtr)0.00
Total Debt (Qtr)24.60 Bn
Revenue Growth (1y) (Qtr)3.21
Add ratio to table…

About

Altria Group, Inc. is a leading producer of tobacco products for consumers aged 21 and older in the United States. The company pursues a vision of moving beyond smoking by responsibly transitioning adult smokers to smoke free alternatives while competing for existing smoke free nicotine consumers and exploring new growth opportunities. Its wholly owned subsidiaries include Philip Morris USA Inc. which manufactures and sells cigarettes; John Middleton Co. which manufactures…

Read more ↓
Sector: Consumer Defensive Industry: Tobacco CIK: 0000764180

Investment Thesis

▲ Bull case
  • The most significant catalyst being underestimated by the market is the potential for sustained operational efficiencies from U.S. Smokeless Tobacco Company's (USSTC) manufacturing consolidation, where transitioning production from Nashville to a modern Hopkinsville facility eliminates fixed cost inefficiencies in a smaller 270,000-square-foot plant versus the legacy 800,000-square-foot site, directly generating operational savings without requiring top-line growth; this structural cost advantage, combined with the planned sale of the over 30-acre Nashville campus, creates a hidden margin expansion lever that management did not emphasize during the earnings call despite its long-term profitability impact, as the phased transition concluding in early 2028 positions Altria to reinvest savings into higher-growth smoke-free categories while maintaining robust cash flow from its core combustible business.
  • The market overlooks the strategic value of Altria's enforcement-discretion policy alignment with the FDA's new looser vaping regulation, which allows compliant manufacturers to sell previously unauthorized products if applications meet scientific standards, creating a near-term pathway for Helix to accelerate on! PLUS flavor extensions and NJOY to reintroduce ACE-like products without enduring the full 180-day PMTA review; this regulatory shift, driven by industry lobbying and evidenced by 1,000+ applications at scientific review stage, represents an unspoken catalyst that could rapidly expand Altria's addressable market in the $8 billion illicit vape segment by converting illegal sales to authorized, high-margin offerings, yet management framed e-vapor progress narrowly around enforcement rather than highlighting this authorization acceleration as a discretionary growth lever.
  • Investors fail to appreciate how Altria's revenue growth management (RGM) tools are creating a self-reinforcing premiumization engine within the smokeable segment, where Marlboro's premium share expansion to 59.5% (up 0.1 points YoY) is driven not by volume but by data analytics enabling store-by-store competitive pricing that maintains 65.1% adjusted OCI margins despite declining total cigarette volumes; this capability allows Altria to monetize brand loyalty in the profitable premium tier while simultaneously using Basic to capture discount share gains from economic pressure, effectively isolating margin dilution to lower-margin segments and preserving overall profitability—a dynamic management acknowledged but did not frame as a scalable, structural advantage against macroeconomic headwinds.
▼ Bear case
  • Altria's guidance reaffirmation despite Q1 EPS growth of 7.3% reveals an unspoken concern about the durability of the cross-category moderation between cigarettes and illicit vapes, as management explicitly tied the stronger-than-expected quarter to temporary offsets like higher-than-normal tax refunds and declining gas prices later in the quarter, which are not sustainable drivers; the CFO admitted macroeconomic uncertainty remains challenging with elevated everyday expenses weighing on discretionary income, and the company's refusal to raise guidance suggests internal skepticism that the volume performance can persist without these transitory tailwinds, indicating the market may be overestimating the sustainability of recent smokeable segment resilience.
  • The bearish case hinges on the structural decline in oral tobacco products, where adjusted OCI margins contracted 1.8 percentage points YoY to 67.4% despite on! shipment volume growing nearly 18%, revealing a hidden profit dilution from Helix's marketing investments for on! PLUS national expansion and unfavorable product mix shift toward lower-margin nicotine pouches versus traditional MST; this margin compression, occurring while total oral tobacco segment retail share fell 5.5 points to 29.0%, signals that investments to capture nicotine pouch category growth are currently destroying more value in the legacy MST business than they are creating, with management acknowledging the trade-off but not disclosing whether the long-term pouch-driven mix shift will ultimately sustain or erode segment profitability.
  • Market optimism ignores the escalating regulatory and reputational risks from Altria's political lobbying activities, as six U.S. senators publicly accused the company of enjoying a "lucrative payday" from donations to curry favor with the Trump administration to circumvent federal oversight via the FDA's enforcement-discretion policy, which critics argue floods the market with untested vapes and nicotine pouches containing harmful chemicals; this scrutiny not only invites potential legislative backlash or stricter future regulation but also undermines Altria's harm reduction narrative, with former FDA officials warning the policy is "really bad for public health" and could erode consumer trust in authorized products—a non-financial risk that management addressed only generically regarding responsibility safeguards without confronting the systemic reputational damage from perceived regulatory capture.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Tobacco
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 MO Altria Group, Inc. 66.91 Bn8.312.8524.60 Bn
2 RLX RLX Technology Inc. 2.38 Bn13.143.530.02 Bn
3 TPB Turning Point Brands, Inc. 1.68 Bn30.343.500.29 Bn
4 UVV Universal Corp /Va/ 1.30 Bn23.300.450.62 Bn
5 ISPR Ispire Technology Inc. 0.07 Bn-1.910.730.00 Bn
6 RYM RYTHM, Inc. 0.05 Bn7.931.820.01 Bn
7 GNLN Greenlane Holdings, Inc. 0.01 Bn-0.102.88-
8 VPRB VPR Brands, LP. 0.00 Bn4.431.410.00 Bn